Symptom management in the older adult. 2015 Update.

Clinics in Geriatric Medicine

Volumn 31, Issue 2, 2015, Pages 155-175

  Smith, Thomas J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Delirium; Depression; Nonpharmacologic management; Older adults; Pain management; Palliative care; Pharmacologic management

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; BUPIVACAINE; CAPSAICIN; CARBAMAZEPINE; CELECOXIB; DENOSUMAB; DESIPRAMINE; DULOXETINE; GABAPENTIN; LIDOCAINE; MERCADANTE; METHADONE; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PAMIDRONIC ACID; PLACEBO; PREGABALIN; ROFECOXIB; TAPENTADOL; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; VALPROIC ACID; VENLAFAXINE; ZOLEDRONIC ACID;

ANALGESIA; BONE PAIN; CONSTIPATION; COUGHING; DELIRIUM; DEPRESSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; EVENING DOSAGE; FATIGUE; FECES IMPACTION; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HICCUP; HORMONE RELEASE; HUMAN; INTESTINE OBSTRUCTION; KIDNEY FUNCTION; LOW DRUG DOSE; MENTAL DISEASE; MORNING DOSAGE; MUSCLE MASS; MYELINATION; MYOFASCIAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; PALLIATIVE THERAPY; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRURITUS; PSYCHOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN MANIFESTATION; SYMPTOMATOLOGY; VOMITING; AGED; CLASSIFICATION; CLINICAL PRACTICE; NEEDS ASSESSMENT; PAIN; PAIN MEASUREMENT; PROCEDURES; STANDARDS; SYMPTOM ASSESSMENT; TOTAL QUALITY MANAGEMENT;

AGED; HUMANS; NEEDS ASSESSMENT; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PALLIATIVE CARE; PRACTICE PATTERNS, PHYSICIANS'; QUALITY IMPROVEMENT; SYMPTOM ASSESSMENT;

EID: 84928582573     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2015.01.006     Document Type: Review

References (94)

1. Brown J.A., Von Roenn J.H. Symptom management in the older adult. Clin Geriatr Med 2004, 20(4):621-640. [review], v-vi.
2. Fisch M.J., Lee J.W., Weiss M., et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. JClin Oncol 2012, 30(16):1980-1988.
3. Okie S. Aflood of opioids, a rising tide of deaths. NEngl J Med 2010, 363:1981-1985.
4. Makris U.E., Abrams R.C., Gurland B., et al. Management of persistent pain in the older patient: a clinical review. JAMA 2014, 312(8):825-836.
5. Drugs.com. Oxycodone prices, coupons and patient assistance programs. Available at: Accessed September 19, 2014. http://www.drugs.com/price-guide/oxycodone#oral-tablet-extended-release-10-mg.
6. Jensen M.P. Aneuropsychological model of pain: research and clinical implications. JPain 2010, 11(1):2-12.
7. Burakgazi A.Z., Messersmith W., Vaidya D., et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011, 77(10):980-986.
8. Cruccu G., Sommer C., Anand P., et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010, 17(8):1010-1018.
9. Gilron I., Bailey J.M., Tu D., et al. Morphine, gabapentin, or their combination for neuropathic pain. NEngl J Med 2005, 352(13):1324-1334.
10. Gaskell H., Moore R.A., Derry S. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014, (6). CD010692.
11. Pergolizzi J., Böger R.H., Budd K., et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008, 8(4):287-313.
12. Bruera E., Palmer J.L., Bosnjak S., et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. JClin Oncol 2004, 22(1):185-192.
13. Moore R.A., Wiffen P.J., Derry S., et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014, (4). CD007938.
14. Moulin D., Boulanger A., Clark A.J., et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014, 19(6):328-335.
15. Smith E.M., Bakitas M.A., Homel P., et al. Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer. JPain Symptom Manage 2011, 42(6):822-838.
16. Berry J.D., Petersen K.L. Asingle dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005, 65(3):444-447.
17. Jensen-Dahm C., Rowbotham M.C., Reda H. Effect of a single dose of pregabalin on herpes zoster pain. Trials 2011, 12:55.
18. Johnson R.W., Rice A.S. Clinical practice. Postherpetic neuralgia. NEngl J Med 2014, 371(16):1526-1533.
19. Durand J.P., Deplanque G., Montheil V., et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012, 23(1):200-205.
20. Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013, 309(13):1359-1367. Alliance for Clinical Trials in Oncology.
21. Hershman D.L., Lacchetti C., Dworkin R.H., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. JClin Oncol 2014, 32(18):1941-1967. American Society of Clinical Oncology.
22. Chochinov H.M., Wilson K.G., Enns M., et al. "Are you depressed?" Screening for depression in the terminally ill. Am J Psychiatry 1997, 154(5):674-676.
23. Zimmerman M., Ruggero C.J., Chelminski I., et al. Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life. JClin Psychiatry 2006, 67(10):1536-1541.
24. Hughes E.F., Wu A.W., Carducci M.A., et al. What can I do? Recommendations for responding to issues identified by patient-reported outcomes assessments used in clinical practice. JSupport Oncol 2012, 10(4):143-148. [review].
25. Hurlow A., Bennett M.I., Robb K.A., et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev 2012, (3). [review], CD006276.
26. Colvin L.A., Johnson P.R., Mitchell R., et al. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. JClin Oncol 2008, 26(27):4519-4520.
27. Smith T.J., Coyne P.J., Parker G.L., et al. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy. JPain Symptom Manage 2010, 40(6):883-891.
28. Pachman D.R., Weisbrod B.L., Seisler D.K., et al. Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer 2014, [Epub ahead of print].
29. Smith T.J., Marineo G. Treatment of postherpetic pain with scrambler therapy, a patient-specific neurocutaneous electrical stimulation device. Am J Hosp Palliat Care 2013, [Epub ahead of print].
30. Guiseppe M., Vittorio I., Cristiano G., et al. MC5-A scrambler therapy relieves chronic neuropathic pain more effectively than guideline based drug management. JPain Symptom Manage 2012, 43(1):87-95.
31. Swislocki A., Orth M., Bales M., et al. Arandomized clinical trial of the effectiveness of photon stimulation on pain, sensation, and quality of life in patients with diabetic peripheral neuropathy. JPain Symptom Manage 2010, 39(1):88-99.
32. Heiskanen T., Mätzke S., Haakana S., et al. Transdermal fentanyl in cachectic cancer patients. Pain 2009, 144(1-2):218-222.
33. Prommer E.E. Tramadol: does it have a role in cancer pain management?. JOpioid Manag 2005, 1(3):131-138.
34. Arbaiza D., Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig 2007, 27(1):75-83.
35. Candiotti K.A., Gitlin M.C. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?. Curr Med Res Opin 2010, 26(7):1677-1684.
36. Wilcock A., Beattie J.M. Prolonged QT interval and methadone: implications for palliative care. Curr Opin Support Palliat Care 2009, 3(4):252-257.
37. Derry S., Moore R.A., Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012, (9). CD007400.
38. Lin Y.C., Kuan T.S., Hsieh P.C., et al. Therapeutic effects of lidocaine patch on myofascial pain syndrome of the upper trapezius: a randomized, double-blind, placebo-controlled study. Am J Phys Med Rehabil 2012, 91(10):871-882.
39. Patrick D.L., Cleeland C.S., von Moos R., et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer 2014, [Epub ahead of print].
40. Scott L.J., Muir V.J. Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours. Drugs 2011, 71(8):1059-1069.
41. Coleman R., Body J.J., Aapro M., et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014, 25(Suppl 3):iii124-iii137. ESMO Guidelines Working Group.
42. Schuster J.M., Smith T.J., Coyne P.J., et al. Clinic offering affordable radiation therapy to increase access to care for patients enrolled in hospice. JOncol Pract 2014, 10(6):e390-e395.
43. Mercadante S., Villari P., Ferrera P., et al. Optimization of opioid therapy for preventing incident pain associated with bone metastases. JPain Symptom Manage 2004, 28(5):505-510.
44. Mercadante S., Villari P., Ferrera P., et al. Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Clin J Pain 2009, 25(7):648-649.
45. Mercadante S., Villari P., Ferrera P. Pamidronate in incident pain due to bone metastases. JPain Symptom Manage 2001, 22(2):630-631.
46. Xander C., Meerpohl J.J., Galandi D., et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2013, 6. CD008320.
47. Siemens W., Xander C., Meerpohl J.J., et al. Drug treatments for pruritus in adult palliative care. Dtsch Arztebl Int 2014, 111(50):863-870.
48. Unotoro J., Nonaka E., Takita N., et al. Paroxetine treatment of 3 cases of cholestatic pruritus due to gastrointestinal malignancy. Nihon Shokakibyo Gakkai Zasshi 2010, 107(2):257-262. [Japanese].
49. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45(3):666-674.
50. Ryan N.M., Birring S.S., Gibson P.G. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380(9853):1583-1589.
51. Ryan N.M. Areview on the efficacy and safety of gabapentin in the treatment of chronic cough. Expert Opin Pharmacother 2015, 16(1):135-145.
52. Barton D.L., Liu H., Dakhil S.R., et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. JNatl Cancer Inst 2013, 105(16):1230-1238.
53. Yennurajalingam S., Frisbee-Hume S., Palmer J.L., et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. JClin Oncol 2013, 31(25):3076-3082.
54. Bruera E., Driver L., Barnes E.A., et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. JClin Oncol 2003, 21(23):4439-4443.
55. Bruera E., Valero V., Driver L., et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. JClin Oncol 2006, 24(13):2073-2078.
56. Moraska A.R., Sood A., Dakhil S.R., et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. JClin Oncol 2010, 28(23):3673-3679.
57. Spathis A., Fife K., Blackhall F., et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. JClin Oncol 2014, 32(18):1882-1888.
58. Breitbart W., Alici Y. Psychostimulants for cancer-related fatigue. JNatl Compr Canc Netw 2010, 8(8):933-942. [review].
59. Yennurajalingam S., Palmer J.L., Chacko R., et al. Factors associated with response to methylphenidate in advanced cancer patients. Oncologist 2011, 16(2):246-253.
60. Lynn J., Teno J.M., Phillips R.S., et al. Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 1997, 126(2):97-106.
61. Uronis H.E., Currow D.C., McCrory D.C., et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer 2008, 98(2):294-299.
62. Abernethy A.P., McDonald C.F., Frith P.A., et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010, 376(9743):784-793.
63. Uronis H., McCrory D.C., Samsa G., et al. Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, (6). [review], CD006429.
64. Ameer F., Carson K.V., Usmani Z.A., et al. Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest. Cochrane Database Syst Rev 2014, (6). CD000238.
65. Varkey B. Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010, 16(2):150-154.
66. Johnson M.J., Hui D., Currow D.C. Opioids, exertion, and dyspnea: a review of the evidence. Am J Hosp Palliat Care 2014, [pii:1049909114552692]. [Epub ahead of print].
67. Gifford A.H., Mahler D.A., Waterman L.A., et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD 2011, 8(3):160-166.
68. Currow D.C., McDonald C., Oaten S., et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. JPain Symptom Manage 2011, 42(3):388-399.
69. Allcroft P., Margitanovic V., Greene A., et al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. JPalliat Med 2013, 16(7):741-744.
70. Simon S.T., Niemand A.M., Benalia H., et al. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. JPalliat Med 2012, 15(12):1374-1381.
71. Marciniuk D., Goodridge D., Hernandez P., et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011, 18(2):69-78.
72. Coyne P., Ramakrishnan V., Smith T.J. Nebulized fentanyl improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. JPain Symptom Manage 2002, 23:157-160.
73. Smith T.J., Coyne P., French W., et al. Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned. JPalliat Med 2009, 12(9):771-772.
74. Hirsch C.A., Marriott J.F., Faull C.M. Influences on the decision to prescribe or administer anticholinergic drugs to treat death rattle: a focus group study. Palliat Med 2013, 27(8):732-738.
75. Mercadamte S. Death rattle: critical review and research agenda. Support Care Cancer 2014, 22(2):571-575.
76. Lokker M.E., van Zuylen L., van der Rijt C.C., et al. Prevalence, impact, and treatment of death rattle: a systematic review. JPain Symptom Manage 2014, 47(1):105-122.
77. Flicker C., Ferris S.H., Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl) 1992, 107(2-3):437-441.
78. Twomey S., Dowling M. Management of death rattle at end of life. Br J Nurs 2013, 22(2):81-85.
79. Hardy S.E. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009, 7(1):34-59.
80. Transcranial Magnetic Stimulation for the Treatment of Adults with PTSD, GAD, or Depression: A Review of Clinical Effectiveness and Guidelines [Internet]. CADTH Rapid Response Reports 2014, Canadian Agency for Drugs and Technologies in Health, Ottawa (ON).
81. Allan C.L., Herrmann L.L., Ebmeier K.P. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology 2011, 64(3):163-169.
82. Inouye S.K., van Dyck C.H., Alessi C.A., et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990, 113(12):941-948.
83. Available at: Accessed September 19, 2014. http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_125.htm.
84. Hui D., Bush S.H., Gallo L.E., et al. Neuroleptic dose in the management of delirium in patients with advanced cancer. JPain Symptom Manage 2010, 39(2):186-196.
85. Tarumi Y., Wilson M.P., Szafran O., et al. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. JPain Symptom Manage 2013, 45(1):2-13.
86. Thomas J., Karver S., Cooney G.A., et al. Methylnaltrexone for opioid-induced constipation in advanced illness. NEngl J Med 2008, 358(22):2332-2343.
87. Salpeter S.R., Malter D.S., Luo E.J., et al. Systematic review of cancer presentations with a median survival of six months or less. JPalliat Med 2012, 15(2):175-185. [review].
88. Mercadante S., Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol 2012, 83(3):388-392.
89. Currow D.C., Quinn S., Agar M., et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. JPain Symptom Manage 2014, 10.1016/j.jpainsymman.2014.09.013.
90. Smith T.J., Ritter J.K., Poklis J.L., et al. ABH gel is not absorbed from the skin of normal volunteers. JPain Symptom Manage 2012, 43(5):961-966.
91. Fletcher D.S., Coyne P.J., Dodson P.W., et al. Arandomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. JPain Symptom Manage 2014, 48(5):797-803.
92. Gupta M., Davis M., LeGrand S., et al. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. JSupport Oncol 2013, 11(1):8-13.
93. Hocking C.M., Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 2014, 22(4):1143-1151. [review].
94. Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care 2013, 30(1):75-82. [review].